|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SRSF5 |
Gene summary for SRSF5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SRSF5 | Gene ID | 6430 |
| Gene name | serine and arginine rich splicing factor 5 | |
| Gene Alias | HRS | |
| Cytomap | 14q24.1 | |
| Gene Type | protein-coding | GO ID | GO:0000245 | UniProtAcc | A0A024R6D8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6430 | SRSF5 | GSM4909282 | Human | Breast | IDC | 7.54e-05 | -3.02e-01 | -0.0288 |
| 6430 | SRSF5 | GSM4909286 | Human | Breast | IDC | 8.45e-15 | -4.38e-01 | 0.1081 |
| 6430 | SRSF5 | GSM4909287 | Human | Breast | IDC | 1.77e-02 | -3.52e-01 | 0.2057 |
| 6430 | SRSF5 | GSM4909291 | Human | Breast | IDC | 2.69e-03 | -4.42e-01 | 0.1753 |
| 6430 | SRSF5 | GSM4909294 | Human | Breast | IDC | 2.09e-08 | -4.13e-01 | 0.2022 |
| 6430 | SRSF5 | GSM4909296 | Human | Breast | IDC | 4.38e-14 | -4.19e-01 | 0.1524 |
| 6430 | SRSF5 | GSM4909297 | Human | Breast | IDC | 3.22e-16 | -9.72e-02 | 0.1517 |
| 6430 | SRSF5 | GSM4909301 | Human | Breast | IDC | 5.27e-12 | -4.78e-01 | 0.1577 |
| 6430 | SRSF5 | GSM4909304 | Human | Breast | IDC | 2.77e-05 | -4.02e-01 | 0.1636 |
| 6430 | SRSF5 | GSM4909305 | Human | Breast | IDC | 4.62e-05 | 3.32e-01 | 0.0436 |
| 6430 | SRSF5 | GSM4909311 | Human | Breast | IDC | 3.62e-36 | -5.36e-01 | 0.1534 |
| 6430 | SRSF5 | GSM4909312 | Human | Breast | IDC | 1.26e-06 | -2.33e-01 | 0.1552 |
| 6430 | SRSF5 | GSM4909315 | Human | Breast | IDC | 1.22e-11 | -4.88e-01 | 0.21 |
| 6430 | SRSF5 | GSM4909316 | Human | Breast | IDC | 2.79e-03 | -5.43e-01 | 0.21 |
| 6430 | SRSF5 | GSM4909319 | Human | Breast | IDC | 1.20e-48 | -5.46e-01 | 0.1563 |
| 6430 | SRSF5 | GSM4909320 | Human | Breast | IDC | 7.99e-15 | -7.37e-01 | 0.1575 |
| 6430 | SRSF5 | GSM4909321 | Human | Breast | IDC | 1.61e-19 | -4.48e-01 | 0.1559 |
| 6430 | SRSF5 | brca2 | Human | Breast | Precancer | 2.43e-02 | 9.85e-02 | -0.024 |
| 6430 | SRSF5 | brca10 | Human | Breast | Precancer | 2.82e-05 | -4.37e-01 | -0.0029 |
| 6430 | SRSF5 | M5 | Human | Breast | IDC | 5.19e-04 | 4.21e-01 | 0.1598 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00713753 | Colorectum | FAP | cellular response to peptide hormone stimulus | 75/2622 | 290/18723 | 5.60e-08 | 4.29e-06 | 75 |
| GO:00328683 | Colorectum | FAP | response to insulin | 68/2622 | 264/18723 | 2.71e-07 | 1.55e-05 | 68 |
| GO:00718264 | Colorectum | FAP | ribonucleoprotein complex subunit organization | 59/2622 | 227/18723 | 1.18e-06 | 5.26e-05 | 59 |
| GO:00328693 | Colorectum | FAP | cellular response to insulin stimulus | 54/2622 | 203/18723 | 1.54e-06 | 6.59e-05 | 54 |
| GO:00226184 | Colorectum | FAP | ribonucleoprotein complex assembly | 57/2622 | 220/18723 | 1.99e-06 | 8.03e-05 | 57 |
| GO:00610084 | Colorectum | FAP | hepaticobiliary system development | 41/2622 | 150/18723 | 1.32e-05 | 3.55e-04 | 41 |
| GO:00018894 | Colorectum | FAP | liver development | 40/2622 | 147/18723 | 1.88e-05 | 4.70e-04 | 40 |
| GO:00226134 | Colorectum | FAP | ribonucleoprotein complex biogenesis | 91/2622 | 463/18723 | 4.28e-04 | 5.12e-03 | 91 |
| GO:00331203 | Colorectum | FAP | positive regulation of RNA splicing | 13/2622 | 37/18723 | 1.03e-03 | 1.00e-02 | 13 |
| GO:00434845 | Colorectum | CRC | regulation of RNA splicing | 43/2078 | 148/18723 | 1.75e-09 | 5.31e-07 | 43 |
| GO:00083805 | Colorectum | CRC | RNA splicing | 90/2078 | 434/18723 | 2.80e-09 | 7.97e-07 | 90 |
| GO:00487325 | Colorectum | CRC | gland development | 88/2078 | 436/18723 | 1.62e-08 | 2.79e-06 | 88 |
| GO:00003775 | Colorectum | CRC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 66/2078 | 320/18723 | 4.39e-07 | 3.37e-05 | 66 |
| GO:00003985 | Colorectum | CRC | mRNA splicing, via spliceosome | 66/2078 | 320/18723 | 4.39e-07 | 3.37e-05 | 66 |
| GO:00003755 | Colorectum | CRC | RNA splicing, via transesterification reactions | 66/2078 | 324/18723 | 7.00e-07 | 4.61e-05 | 66 |
| GO:00610085 | Colorectum | CRC | hepaticobiliary system development | 37/2078 | 150/18723 | 2.09e-06 | 1.02e-04 | 37 |
| GO:00226185 | Colorectum | CRC | ribonucleoprotein complex assembly | 48/2078 | 220/18723 | 3.16e-06 | 1.44e-04 | 48 |
| GO:00018895 | Colorectum | CRC | liver development | 36/2078 | 147/18723 | 3.41e-06 | 1.50e-04 | 36 |
| GO:00718265 | Colorectum | CRC | ribonucleoprotein complex subunit organization | 49/2078 | 227/18723 | 3.44e-06 | 1.51e-04 | 49 |
| GO:00434344 | Colorectum | CRC | response to peptide hormone | 76/2078 | 414/18723 | 6.67e-06 | 2.56e-04 | 76 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa030408 | Breast | Precancer | Spliceosome | 39/684 | 217/8465 | 1.44e-06 | 2.27e-05 | 1.74e-05 | 39 |
| hsa0304013 | Breast | Precancer | Spliceosome | 39/684 | 217/8465 | 1.44e-06 | 2.27e-05 | 1.74e-05 | 39 |
| hsa0304023 | Breast | IDC | Spliceosome | 40/867 | 217/8465 | 1.53e-04 | 1.42e-03 | 1.06e-03 | 40 |
| hsa0304033 | Breast | IDC | Spliceosome | 40/867 | 217/8465 | 1.53e-04 | 1.42e-03 | 1.06e-03 | 40 |
| hsa0304043 | Breast | DCIS | Spliceosome | 40/846 | 217/8465 | 8.97e-05 | 8.52e-04 | 6.28e-04 | 40 |
| hsa0304053 | Breast | DCIS | Spliceosome | 40/846 | 217/8465 | 8.97e-05 | 8.52e-04 | 6.28e-04 | 40 |
| hsa03040 | Colorectum | AD | Spliceosome | 73/2092 | 217/8465 | 1.73e-03 | 9.68e-03 | 6.18e-03 | 73 |
| hsa030401 | Colorectum | AD | Spliceosome | 73/2092 | 217/8465 | 1.73e-03 | 9.68e-03 | 6.18e-03 | 73 |
| hsa030402 | Colorectum | MSS | Spliceosome | 66/1875 | 217/8465 | 2.58e-03 | 1.27e-02 | 7.81e-03 | 66 |
| hsa030403 | Colorectum | MSS | Spliceosome | 66/1875 | 217/8465 | 2.58e-03 | 1.27e-02 | 7.81e-03 | 66 |
| hsa030409 | Endometrium | AEH | Spliceosome | 54/1197 | 217/8465 | 1.47e-05 | 1.65e-04 | 1.21e-04 | 54 |
| hsa0304014 | Endometrium | AEH | Spliceosome | 54/1197 | 217/8465 | 1.47e-05 | 1.65e-04 | 1.21e-04 | 54 |
| hsa0304024 | Endometrium | EEC | Spliceosome | 54/1237 | 217/8465 | 3.78e-05 | 3.88e-04 | 2.89e-04 | 54 |
| hsa0304034 | Endometrium | EEC | Spliceosome | 54/1237 | 217/8465 | 3.78e-05 | 3.88e-04 | 2.89e-04 | 54 |
| hsa0304027 | Esophagus | ESCC | Spliceosome | 128/4205 | 217/8465 | 3.31e-03 | 8.79e-03 | 4.50e-03 | 128 |
| hsa0304037 | Esophagus | ESCC | Spliceosome | 128/4205 | 217/8465 | 3.31e-03 | 8.79e-03 | 4.50e-03 | 128 |
| hsa030407 | Liver | Cirrhotic | Spliceosome | 102/2530 | 217/8465 | 5.69e-08 | 9.47e-07 | 5.84e-07 | 102 |
| hsa0304012 | Liver | Cirrhotic | Spliceosome | 102/2530 | 217/8465 | 5.69e-08 | 9.47e-07 | 5.84e-07 | 102 |
| hsa0304022 | Liver | HCC | Spliceosome | 122/4020 | 217/8465 | 5.55e-03 | 1.60e-02 | 8.91e-03 | 122 |
| hsa0304032 | Liver | HCC | Spliceosome | 122/4020 | 217/8465 | 5.55e-03 | 1.60e-02 | 8.91e-03 | 122 |
| Page: 1 2 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SRSF5 | SNV | Missense_Mutation | c.325N>T | p.Arg109Cys | p.R109C | Q13243 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AO-A0JM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| SRSF5 | SNV | Missense_Mutation | c.38N>G | p.Pro13Arg | p.P13R | Q13243 | protein_coding | tolerated(0.2) | possibly_damaging(0.739) | TCGA-C5-A1BM-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SRSF5 | SNV | Missense_Mutation | rs141668513 | c.614N>A | p.Arg205His | p.R205H | Q13243 | protein_coding | deleterious(0.04) | benign(0.001) | TCGA-EK-A2PG-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
| SRSF5 | SNV | Missense_Mutation | rs746899808 | c.304N>T | p.Pro102Ser | p.P102S | Q13243 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-EX-A69M-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| SRSF5 | SNV | Missense_Mutation | novel | c.127N>A | p.Glu43Lys | p.E43K | Q13243 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
| SRSF5 | SNV | Missense_Mutation | rs759069069 | c.410N>T | p.Ala137Val | p.A137V | Q13243 | protein_coding | tolerated(0.07) | benign(0.153) | TCGA-AA-3666-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
| SRSF5 | SNV | Missense_Mutation | novel | c.66N>C | p.Arg22Ser | p.R22S | Q13243 | protein_coding | deleterious(0) | possibly_damaging(0.828) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| SRSF5 | SNV | Missense_Mutation | c.474N>T | p.Lys158Asn | p.K158N | Q13243 | protein_coding | deleterious(0) | probably_damaging(0.966) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| SRSF5 | SNV | Missense_Mutation | novel | c.378T>G | p.Asp126Glu | p.D126E | Q13243 | protein_coding | deleterious(0) | possibly_damaging(0.893) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| SRSF5 | SNV | Missense_Mutation | c.509N>G | p.Asn170Ser | p.N170S | Q13243 | protein_coding | tolerated(0.05) | benign(0.191) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |